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Immune complexes (ICs) are produced during an immune response and may reflect some 
aspects of an ongoing immune response.  Therefore, the identity of antigens incorporated into ICs 
provides the information that in the future may aid in the development of diagnosis and treatment 
strategies for autoimmune diseases, infection, cancer, and transplantation therapy, and this 
information might be more relevant than information on free antigens.  Because ICs may contain 
many antigens, comprehensive identification and profiling of such antigens is more effective than 
immunoblotting detection.  Here, we introduced mass spectrometry (MS) -based two approaches 
(immunoproteomics and immune complexome analsyis) to comprehensively identify the antigens.  
Immunoproteomics is a concept to identify disease-associated antigens that elicit immune responses 
by combining protein separation (2-dimensional electrophoresis, gel-free separation), 
immunological detection (Western blotting) and MS, or combining immunocapture and MS.  
Immune complexome analysis is designed for identifying antigens in circulating ICs and consists of 




2. Immune complex 
     Our immune system resembles an intelligent security system, which continually monitors for 
foreign invaders; however, in some cases, this system recognizes the healthy parts as something 
harmful or foreign, and attacks them (autoimmune diseases).  Immune complexes (ICs) are 
products of reactions that involve non-covalent interactions between foreign antigens or autoantigen 
and antibody molecules.  IC formation constantly occurs even in healthy organisms; denatured 
proteins, antigens of gut bacteria, and dead cells undergo binding to antibodies followed by 
subsequent phagocytosis, mainly by macrophages located in the liver and spleen [1].  For a long 
time, ICs were thought to represent a common pathway for pathogenesis of several diseases 
(vasculitis, infections, and connective tissue autoimmune disorders).  The pathology generally 
arises from insufficient clearance or deposition of ICs.  Actually, ICs in the sera of the patients 
with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis was 
significantly higher than that of healthy controls [2, 3].  Also, aberrant host proteins that occur 
during a certain state of diseases (e.g. cancer) can be recognized as an autoantigen and may form 
ICs [4, 5].  Reasons why the ICs underlie pathogenicity have been investigated by many 
researchers [6-8].  Clinical significance of deposited ICs in glomerulonephritis is well understood 
[9-11]; however, the relationship between ICs and many diseases are still unclear.  Therefore, 
information on ICs is useful to reveal if ICs play an important role in each disease.  Especially, 
identifying relevant antigens is informative because they trigger the humoral immune response.  In 
future, such information may possibly provide new insights into pathophysiology and form the 
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basis for novel diagnostic and treatment strategies for autoimmune diseases, infection and cancer. 
 
3. Identification of disease-associated antigens 
   ICs present in the human body are likely to contain many different antigens that may reflect 
underlying disease and/or differences between individuals. Therefore, comprehensive identification 
and profiling of such antigens may be more effective than immunoblotting detection of individual 
antigens.  Microarrays are widely used to detect multiple antigens [12].  This approach depends 
on exposing serum samples from patients to an ordered array of putative antigens, capturing those 
antibodies that bind the antigens on the arrays.  However, two major drawbacks of the array are 
that it is biased, given that antigens are selected based on the likelihood that they play a role in the 
disease and that the analytical comprehensiveness of this technique is fundamentally limited 
because only molecules represented on the arrays can be identified [13]. 
Contrastingly, with the progress in both mass spectrometry (MS) and bioinfomatics, proteomic 
methods are fully developed and become common.  Especially, a 2-dimensional liquid 
chromatography/tandem MS (2D-LC-MS/MS), or a combination of 2-dimensional gel 
electrophoresis (2-DE) and matrix laser desorption/ionization time-of-flight MS (MALDI-TOF-MS), 
which are followed by database-searching (sequence tag or peptide mass fingerprinting), is widely 
used.  These methods drastically expand the comprehensiveness of protein identification; thus, the 
paradigm in biomarker research during the last decades has been shifted from hypothesis-driven to 
discovery-driven approaches.  Based on those MS-based proteomic techniques, several attempts to 
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identify disease-associated antigens have been reported. 
 
3.1 Immunoproteomics 
Immunoproteomics is a concept to identify disease-associated antigens that elicit immune 
responses by combining protein separation (2-DE, gel-free separation), immunological detection 
(Western blotting) and MS (Fig. 1A), or combining immunocapture and MS (Fig. 1B) [14]. 
Proteins derived from cells or tissues (e.g. cancer cell) were separated by 2-DE.  Antigenic 
proteins are detected by applying patient serum, which may include the antibodies specific to a 
disease, and subsequently using enzyme-labelled secondary antibodies.  To identify immunogenic 
proteins, the corresponding spots are excised from gel and are in-gel digested.  The digest is 
analyzed by MS or tandem MS, followed by peptide fingerprinting or sequence tag methods (Fig. 
1A). 
   In contrast, antigen profiling by immunocapture MS begins with the immobilization of 
antibodies derived from patient serum (Fig. 1B).  Almost all the antibodies are captured on Protein 
A or G which are bacterial-derived proteins and have specific affinity for the Fc domain of 
antibodies.  Then, a protein mixture (cell or tissue lysate) was applied to a column or beads on 
which antibodies are immobilized, resulting in capturing antigens specific to antibodies present in 
patient serum.  Finally, antigens eluted from the antibodies are applied to identify the proteins by 
MALDI-TOF-MS or surface-enhanced laser desorption/ionization MS.  Using this immunocapture 
MS approach, Tjalsma et al. detected antigen profiles in colon cancer patients [15, 16].  Based on 
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the association of Streptococcus bovis with colon cancer, they prepared antigen candidate from S. 
bovis strain and identified bacterial antigens which were captured by antibodies derived from colon 
cancer patients [15].  Furthermore, the same authors also combined the immunocapture technique 
with an MS/MS analysis in a study aimed at identifying diagnostic antigens, which could not be 
identified in previous study [15], from S. bovis [16].  In this method, the antigens captured by 
antibodies in patient serum were eluted and are applied to in-solution tryptic digestion.  All the 
digested peptides were separated on nano-LC column and subsequently sequenced by MS/MS 
spectra and protein database, which is called shotgun immunoproteomics [16]. 
 
3.2 Immune complexome analysis 
Importantly, the identification of antigens in circulating immune complex (CIC) might be 
different from that of free antigens because CICs are the direct and real-time products of an immune 
response.  CICs may sensitively reflect the pathophysiological change at the early stage or during 
the progression of a disease.  Moore and colleagues reported a proteomic approach for profiling 
CIC in which CICs were isolated from the sera of juvenile idiopathic arthritis patients or healthy 
controls by ProceptorTM (ProGen Biologics), and subsequently were separated by 2-DE [17].  
They found that thirty seven protein spots were overexpressed in CICs of the aggressive disease 
groups as compared to controls, 28 of which have been identified.  However, most of protein spots 
identified in this study were derived from immunoglobulins and much information on antigens 
incorporated into CICs could not been obtained. 
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Ohyama et al. propose a novel proteomic strategy (immune complexome analysis, Fig. 2) that 
entails separation of ICs from serum, direct tryptic digestion, and nano-LC-MS/MS for the 
identification and profiling of antigens in CICs by using serum of patients and healthy donors [18].  
CICs were purified by magnetic beads with immobilized Protein G (PureProteome®, Millipore).  
Beads (40 µl) were incubated with 10 µl of serum diluted with phosphate buffered saline (PBS, 1:9, 
v/v) for 30 min with gentle mixing.  The beads with bound ICs were recovered with a magnet and 
washed three times with 500 µl of PBS.  The beads were resuspended in 100 µl of 10 mM 
dithiothreitol and incubated at 56 ºC for 45 min; then, 100 µl of 55 mM iodoacetamide were added 
and the mixture was incubated at room temperature for 30 min in the dark.  Subsequently, trypsin 
was added, and the mixture was incubated overnight at 37 ºC.  Trifluoroacetic acid (10%) was 
added to stop the digestion, and the supernatant containing the peptide digests of antigens and 
antibodies was recovered.  The peptide mixture (1 µl) was subjected to nano-LC-MS/MS.    
MS/MS data were searched against a human subdatabase from the public non-redundant protein 
database.  Initial matching results were further evaluated by the filter criteria which were adjusted 
maintaining the empirically determined false discovery rate (FDR) at zero.  FDR was calculated 
using the number of significant unique peptide in the reversed database divided by the number of 
those in the forward database.  Ubiquitous keratins and trypsin were excluded as potential matches.  
In order to focus the aim on identifying antigens in CIC, the peptides derived from 
immunoglobulins were also excluded.  More details of immune complexome analysis can be found 




4. Immune complexome analysis of RA patients 
RA is a progressive autoimmune disease characterized by chronic inflammation of the 
peripheral joints.  The presence of ICs in serum and synovial fluid of RA patients is likely to 
contribute to the pathogenesis and to the articular damage, since they are responsible for the 
activation of complement, the stimulation of phagocytes and the release of cytokines, 
metalloproteinases and reactive oxygen intermediates [20-24]. 
RA is diagnosed based on classification criteria set by the American College of Rheumatology 
and serological assessment of two RA biomarkers, rheumatoid factor (RF) and 
anti-citrulline-containing protein/peptide (anti-CCP) antibody [25].  RF is not highly specific 
(81%) for RA; it is found in 4% of healthy persons [26, 27].  Anti-CCP antibody has a greater 
specificity (98%) for RA than RF; however, its sensitivity (68%) is lower than RF (78.6%) [23].  
The proteins identified by immune complexome analysis in established RA patients and controls 
(healthy donors and osteoarthritis (OA) patients) are summarized in Table 1.  The detection of 
several complements (C1, C3, C4) indicated that extraction of ICs from serum and peptide mapping 
by our method were successful.  IgG and C3 were found together on the cartilage surface [28], and 
RA-associated autoantibodies were enriched in synovial fluid [29] relative to serum.  Considering 
that CICs containing some of the antigens (clusterin, apolipoprotein E and vitronectin) identified in 
this study were also found in arthritis joints of RA and OA patients [30], our results suggest that the 
CICs possibly accumulate in lesion sites. 
Of the antigens identified here, thrombospondin-1 (TSP-1) incorporated in CICs was 100% 
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specific for RA and appeared more sensitive (81%) than RF and anti-CCP antibodies (Table 1, Fig. 
3).  In RA patients, TSP-1 has been reported to be present in synovial tissues [31], and plasma 
concentrations of TSP-1 have been shown to be increased [32].  However, no information is 
available about whether TSP-1 is present in ICs.  TSP-1 (M.W. 129,000) is a multifunctional 
glycoprotein and is produced in multiple cells including platelets, leukocytes and endothelial cells.  
Studies of animal models provided evidence that angiogenesis plays an important role in RA [33, 
34].  In mice with collagen-induced arthritis, manifestations of inflammation develop in close 
correlation with the expansion of the synovial vasculature [35].  The administration of 
pro-angiogenic cytokines such as vascular endothelial growth factor (VEGF) [36] increases the 
severity of experimentally induced arthritis.  Furthermore, serum angiogenesis markers, including 
VEGF and angiopoietin-1, are elevated very early in the course of the disease [37].  Because 
TSP-1 is known to be an endogenous inhibitor of angiogenesis [38], the formation of 
TSP-1-containing CICs may promote angiogenesis by eliminating active TSP-1 from circulation.  
However, the potent antiangiogenic properties of TSP-1 may be an effective therapeutic strategy for 
treatment of RA.  Jou et al. demonstrated that direct administration of adenoviral vectors encoding 
TSP-1 significantly ameliorated the clinical course of collagen-induced arthritis in rats [39]. 
Although platelet factor 4 (PF4) was less sensitive (52.4%) than TSP-1, PF4 incorporated in 
CICs was also specifically detected in RA patients for the first time using our method (Table 1, Fig. 
3).  Recently, Xiao et al. demonstrated that the ICs following the binding of anti-PF4 antibodies to 
PF4 were present and stimulated human neutrophil activation and cell adhesion [40].  This 
adhesion mechanism enables leukocytes to migrate from blood and affect inflamed synovium.  
Furthermore, PF4 is known to be an angiostatic chemokine [41], and the production of anti-PF4 
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antibodies can accelerate angiogenesis. 
Anti-CCP antibody is specific (94%-99%) for RA; however, 40% of early RA patients are 
negative for this marker [42].  Therefore, novel biomarkers are urgently required, especially for 
early RA and/or for RA lacking RF and anti-CCP antibody markers (i.e., seronegative RA).  
Already, several biomarkers, including autoantibodies and matrix metalloproteinases, have been 
developed for this purpose [43-45].  We evaluated the diagnostic potential of CIC-associated 
TSP-1 and CIC-associated PF4 in early RA patients who were divided into two groups: a 
seropositive group comprising RF-positive-CCP-positive and RF-positive-CCP-negative patients, 
and a seronegative group comprising only RF-negative-CCP-negative patients.  CIC-associated 
TSP-1 was found only in early RA patients and was not found in controls (Sjögren’s syndrome (SS), 
SLE and healthy donors).  Fifty-five% (22/40) of all the early RA patients, 56% (14/25) of 
seropositive and 53% (8/15) of seronegative patients had CIC-associated TSP-1 (Table 2).  
PF4-containing CICs were found in only three (8%) of the patients with early RA; in contrast, 
PF4-containing CICs were found in 52% of patients with established RA.  Therefore, these 
PF4-containing CICs may promote disease progression.  We demonstrated that CIC-associated 
TSP-1 has high potential as a novel biomarker for diagnosing early and/or seronegative RA.  
Further analyses using a large number of patients are warranted to determine the clinical benefit of 
using this novel biomarker. 
 
5. Conclusion 
   ICs are source suitable for understanding nature and amount of humoral immune response.  
The relationship between ICs and diseases, particularly autoimmune diseases, are still unclear; 
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therefore, identifying the relevant antigens helps one to reveal if ICs play a role in a disease.  
Especially, such identification is at the heart of current approaches for discovering antibody 
biomarkers.  Here, we introduced some approaches to identify the antigens in ICs.  Among them, 
immune complexome analysis, using a simple protocol, is endowed with high throughputness and 
comprehensiveness.  It may be generally applicable to the study of the relationship between ICs 
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Fig. 1  Schemes of immunoproteomic approaches.  A) 2-DE is based on protein separation based 
on pI and molecular weight.  Next, proteins are transferred from the gel and immobilized on a 
membrane by Western blotting.  Antigenic proteins can be detected by applying patient serum to 
the blot, after which bound patient IgGs can be visualized by secondary labeled antibodies.  
Finally, the antigenic spot is excised and analyzed by MS.  B) Antigen profiling by immunocapture 
MS is based on immobilization of patient IgGs, which are directly used to capture and isolate 
antigenic proteins from a complex mixture of proteins. Captured antigens are profiled by MS.  
Reprinted with permission from Ref. 14). 
 
Fig. 2  Immune complexome analysis to profile antigens included in circulating immune 
complexes.  The first step of the protocol involves immune complex capture, using the magnetic 
beads with immobilization of Protein G.  The second step is reduction/alkylation and tryptic 
digestion.  The third step involves analysis of the captured antigens by nano-LC-MS/MS. 
 
Fig. 3  Fragmentation spectra of TSP-1 and PF4 in CIC obtained by nano-LC-MS/MS. Data on the 
masses of each tryptic peptide and of its fragmentation ions were compared to those predicted for 
all tryptic peptides from all proteins in the International Protein Index.
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Table 1  Summary of proteins in ICs extracted from serum. 
Protein
Complement Complement C1r subcomponent
Complement C1s subcomponent
Complement component 1, q subcomponent, B chain precursor
Complement C1q subcomponent subunit A
Complement C1q subcomponent subunit C
Complement component 3
Complement C4-A
Complement component 4B preproprotein
C4b-binding protein alpha chain





Adhesion protein Isoform 1 of Fibronection
Vitronection
Isoform B of Fibulin-1
Others Thrombospondin-1
Histidine-rich glycoprotein
Isoform HMW of Kininogen-1
Putative uncharacterized protein albumin
Galectin-3-binding protein
Vitamin K-dependent protein S
Rheumatoid factor RF-ET9 (fragment)
Rheumatoid factor D5 light chain (fragment)
VH3 protein (fragment)























































































Table 2  Number of patients with early RA carrying CIC-associated TSP-1 or CIC-associated PF4 
 
SS patients (n=16) SLE patients (n=14) Healthy donors (n=11)
Seropositive (n=25) Seronegative (n=15)
TSP-1 14 8 0 0 0
PF4 3 0 0 0 0
Early RA patients (n=40)
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Fig. 2 
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Fig. 3 
 
